WO2018202456A1 - Topical compositions designed to maintain and restore the water homeostasis of the skin - Google Patents

Topical compositions designed to maintain and restore the water homeostasis of the skin Download PDF

Info

Publication number
WO2018202456A1
WO2018202456A1 PCT/EP2018/060310 EP2018060310W WO2018202456A1 WO 2018202456 A1 WO2018202456 A1 WO 2018202456A1 EP 2018060310 W EP2018060310 W EP 2018060310W WO 2018202456 A1 WO2018202456 A1 WO 2018202456A1
Authority
WO
WIPO (PCT)
Prior art keywords
water
skin
compositions according
carboxymethylchitosan
weight percentages
Prior art date
Application number
PCT/EP2018/060310
Other languages
French (fr)
Inventor
Michele Giuseppe Di Schiena
Original Assignee
Ricerfarma S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ricerfarma S.R.L. filed Critical Ricerfarma S.R.L.
Publication of WO2018202456A1 publication Critical patent/WO2018202456A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • the present invention relates to topical compositions comprising ⁇ , ⁇ -carboxymethylchitosan and sucrose octasulfate sodium or potassium salt as active ingredients.
  • the compositions of the invention are useful for maintaining and restoring the water homeostasis of the skin, and can be used in dermatology and cosmetology.
  • Transepidermal water loss is a physiological phenomenon consisting of continuous diffusion of water from the deepest layers to the outermost layers of the skin, where the water evaporates; said physiological process ensures the water homeostasis, which is crucial to maintain the integrity, health and good condition of the skin.
  • a correct water homeostasis allows the performance of the physiological functions of the skin, such as the barrier function, which counteracts excessive evaporation of water originating from the deepest layers of the skin. Conversely, when the water homeostasis is incorrect, the skin lacks plasticity and elasticity, and cannot effectively prevent the penetration of aggressive, allergenic, irritant and toxic foreign substances.
  • An altered skin water homeostasis predisposes the individual to numerous disorders, such as local irritative conditions, redness caused by nappies or clothes rubbing, by stagnation of bodily fluids or by burns, bedsores, vascular disorders and early skin aging.
  • occluding substances such as oils or silicones
  • hydrating and hygroscopic substances lipid substances that restore the barrier function
  • substances that stimulate deep hydration can have adverse effects; for example, occluding substances prevent the physiological evaporation of the water in the outermost layers of the skin (TEWL), leading to alteration of the surface cells and imbalance of the cutaneous microbial flora, with a consequent risk of bacterial, fungal or viral infections.
  • Hygroscopic substances can irritate the skin over time; barrier function regulators, which basically have a lipid nature, readily break down, leading to the formation of irritant and toxic substances, and deep hydration stimulants can interfere with the physiological composition of the skin.
  • ⁇ , ⁇ -carboxymethylchitosan and sucrose octasulfate in the form of water-soluble salts slows but does not prevent TEWL, thus giving rise to marked, lasting hydration of the skin by the water deriving from the physiological function of TEWL (endogenous water).
  • the combination of the invention also lacks the adverse effects of the skin hydration compounds known to date.
  • ⁇ , ⁇ -Carboxymethylchitosan is a known compound whose preparation is reported in US 4,619,995. It is readily available on the market, for example from Heppe Medical Chitosan GmbH, under the trademark Chitoceuticals®.
  • NOCMC is known in the odontostomatological field for its hydrating and film- forming properties, protection of the mucosa against pathogens, and buffering of the physiological pH of the oral cavity.
  • sucrose octasulfate (SOS) aluminium salt/complex known as sucralfate
  • sucralfate The sucrose octasulfate (SOS) aluminium salt/complex, known as sucralfate, has long been used in gastroenterology in the treatment of duodenal and gastric ulcers and oesophagitis, in maintenance treatment of peptic ulcers, and in the treatment and prophylaxis of chemotherapy-induced stomatitis.
  • SOS as aluminium salt/complex When applied by external topical administration, SOS as aluminium salt/complex is used in skin and mucosa treatment compositions for its wound-healing, anti-inflammatory and protective properties.
  • SOS as aluminium salt/complex is not suitable for the purposes of the invention, because it is practically insoluble in water and has no hydrophilic properties, unlike its sodium or potassium salts, which exhibit a high level of water-solubility and no topical or systemic toxicity.
  • the sodium salt is readily available on the market, in solid form or aqueous solution.
  • a 20% w/w aqueous solution is marketed by Euticals S.p.A. (Lodi, Italy).
  • the object of the invention is therefore topical compositions designed to be applied to the skin and mucosa, comprising ⁇ , ⁇ -carboxymethylchitosan and sucrose octasulfate sodium or potassium salt as active ingredients, mixed with appropriate excipients and/or carriers suitable for cosmetic and/or dermato logical use.
  • compositions of the invention are particularly suitable for use in the paediatric and geriatric fields.
  • ⁇ , ⁇ -Carboxymethylchitosan is present in the compositions of the invention in percentages ranging between 0.005%) and 8% by weight, preferably between 0.009%) and 5%) w/w, and more preferably between 0.010%> and 3%.
  • Sucrose octasulfate sodium or potassium salt is present in the compositions of the invention in percentages ranging between 0.010%> and 5.0%> by weight, preferably between 0.050%> and 3.0%>, and more preferably between 0.100%> and 1.0%.
  • compositions of the invention can contain other active ingredients commonly used in dermatology and cosmetology, and can be prepared by conventional methods such as those described in Remington, The Science and Practice of Pharmacy, 20th Edition, using suitable excipients or carriers, as described, for example, in Handbook of Pharmaceutical Excipients, 6th Edition, Pharmaceutical Press.
  • suitable excipients or carriers as described, for example, in Handbook of Pharmaceutical Excipients, 6th Edition, Pharmaceutical Press.
  • Examples of preferred formulations are lotions, gels, oil in water (o/w) or water- in-oil (w/o) emulsions, creams, ointments, sprays and foams.
  • Compositions containing water as carrier are particularly preferred.
  • Example 1 Liquid composition
  • Example 4 Spray composition for preventing bedsores
  • Example 5 Composition for paediatric use
  • Example 6 Composition for geriatric use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are topical compositions comprising N,O-carboxymethylchitosan and sucrose octasulfate sodium or potassium salt as active ingredients.

Description

TOPICAL COMPOSITIONS DESIGNED TO MAINTAIN AND RESTORE THE
WATER HOMEOSTASIS OF THE SKIN
The present invention relates to topical compositions comprising Ν,Ο-carboxymethylchitosan and sucrose octasulfate sodium or potassium salt as active ingredients. The compositions of the invention are useful for maintaining and restoring the water homeostasis of the skin, and can be used in dermatology and cosmetology.
Prior art
Transepidermal water loss (TEWL) is a physiological phenomenon consisting of continuous diffusion of water from the deepest layers to the outermost layers of the skin, where the water evaporates; said physiological process ensures the water homeostasis, which is crucial to maintain the integrity, health and good condition of the skin.
However, various chemical, physical, environmental and pathological causes can alter the water homeostasis of the skin with sometimes serious repercussions on its integrity, health and appearance.
A correct water homeostasis allows the performance of the physiological functions of the skin, such as the barrier function, which counteracts excessive evaporation of water originating from the deepest layers of the skin. Conversely, when the water homeostasis is incorrect, the skin lacks plasticity and elasticity, and cannot effectively prevent the penetration of aggressive, allergenic, irritant and toxic foreign substances. An altered skin water homeostasis predisposes the individual to numerous disorders, such as local irritative conditions, redness caused by nappies or clothes rubbing, by stagnation of bodily fluids or by burns, bedsores, vascular disorders and early skin aging.
In order to restore and maintain the correct water homeostasis of the skin, compounds are used which are classified according to their function, for example occluding substances such as oils or silicones; hydrating and hygroscopic substances; lipid substances that restore the barrier function; and substances that stimulate deep hydration. However, said substances can have adverse effects; for example, occluding substances prevent the physiological evaporation of the water in the outermost layers of the skin (TEWL), leading to alteration of the surface cells and imbalance of the cutaneous microbial flora, with a consequent risk of bacterial, fungal or viral infections. Hygroscopic substances can irritate the skin over time; barrier function regulators, which basically have a lipid nature, readily break down, leading to the formation of irritant and toxic substances, and deep hydration stimulants can interfere with the physiological composition of the skin.
Description of the invention
It has now surprisingly been found that the combination of
Ν,Ο-carboxymethylchitosan and sucrose octasulfate in the form of water-soluble salts slows but does not prevent TEWL, thus giving rise to marked, lasting hydration of the skin by the water deriving from the physiological function of TEWL (endogenous water).
The combination of the invention also lacks the adverse effects of the skin hydration compounds known to date.
Ν,Ο-Carboxymethylchitosan (NOCMC) is a known compound whose preparation is reported in US 4,619,995. It is readily available on the market, for example from Heppe Medical Chitosan GmbH, under the trademark Chitoceuticals®.
NOCMC is known in the odontostomatological field for its hydrating and film- forming properties, protection of the mucosa against pathogens, and buffering of the physiological pH of the oral cavity.
The sucrose octasulfate (SOS) aluminium salt/complex, known as sucralfate, has long been used in gastroenterology in the treatment of duodenal and gastric ulcers and oesophagitis, in maintenance treatment of peptic ulcers, and in the treatment and prophylaxis of chemotherapy-induced stomatitis.
When applied by external topical administration, SOS as aluminium salt/complex is used in skin and mucosa treatment compositions for its wound-healing, anti-inflammatory and protective properties. SOS as aluminium salt/complex is not suitable for the purposes of the invention, because it is practically insoluble in water and has no hydrophilic properties, unlike its sodium or potassium salts, which exhibit a high level of water-solubility and no topical or systemic toxicity.
The sodium salt is readily available on the market, in solid form or aqueous solution. A 20% w/w aqueous solution is marketed by Euticals S.p.A. (Lodi, Italy).
Disclosure of the invention
It has now been found that the combination of Ν,Ο-carboxymethylchitosan and sucrose octasulfate sodium or potassium salt has advantageous properties associated with a synergic effect on hydrophilia, which allows water to be absorbed and retained effectively, slowing transepidermal water loss without preventing it.
The object of the invention is therefore topical compositions designed to be applied to the skin and mucosa, comprising Ν,Ο-carboxymethylchitosan and sucrose octasulfate sodium or potassium salt as active ingredients, mixed with appropriate excipients and/or carriers suitable for cosmetic and/or dermato logical use.
The compositions of the invention are particularly suitable for use in the paediatric and geriatric fields.
Ν,Ο-Carboxymethylchitosan is present in the compositions of the invention in percentages ranging between 0.005%) and 8% by weight, preferably between 0.009%) and 5%) w/w, and more preferably between 0.010%> and 3%.
Sucrose octasulfate sodium or potassium salt is present in the compositions of the invention in percentages ranging between 0.010%> and 5.0%> by weight, preferably between 0.050%> and 3.0%>, and more preferably between 0.100%> and 1.0%.
The compositions of the invention can contain other active ingredients commonly used in dermatology and cosmetology, and can be prepared by conventional methods such as those described in Remington, The Science and Practice of Pharmacy, 20th Edition, using suitable excipients or carriers, as described, for example, in Handbook of Pharmaceutical Excipients, 6th Edition, Pharmaceutical Press. Examples of preferred formulations are lotions, gels, oil in water (o/w) or water- in-oil (w/o) emulsions, creams, ointments, sprays and foams. Compositions containing water as carrier are particularly preferred.
The examples given below further exemplify the invention.
The percentages are expressed as parts by weight of the total volume of the composition
Example 1 - Liquid composition
Sucrose octasulfate sodium salt 1.000%
Ν,Ο-Carboxymethylchitosan 3.000%
Preservative q.s.
Purified water q.s. to 100%
Example 2 - Gel composition
Sucrose octasulfate potassium salt 0.100%>
Ν,Ο-Carboxymethylchitosan 0.010%
Hydroxyethylcellulose 3.000%
Preservative q.s.
Purified water q.s. to 100%
Example 3 - Cream composition
Sucrose octasulfate sodium salt 0.500%)
Ν,Ο-Carboxymethylchitosan 0.300%
Squalane 5.000%
Lactic acid q.s. to pH 5.5
Salcare SC91 3.000%
Preservative q.s.
Purified water q.s. to 100%) Example 4 - Spray composition for preventing bedsores
Sucrose octasulfate sodium salt 0.250%
Ν,Ο-Carboxymethylchitosan 0.500%
Distilled chamomile water 5.000%
Distilled witch-hazel water 5.000%
Horse-chestnut mother tincture 10.000%
Preservative q.s.
Purified water q.s. to 100%
Example 5 - Composition for paediatric use
Sucrose octasulfate sodium salt 0.250%
Ν,Ο-Carboxymethylchitosan 0.100%
Distilled cornflower water 5.000%
Distilled chamomile water 5.000%
Allantoin 0.100%
Preservative q.s.
Sepigel 305 3.000%
Purified water q.s. to 100%
Example 6 - Composition for geriatric use
Sucrose octasulfate sodium salt 1.000%
Ν,Ο-Carboxymethylchitosan 1.000%
Sodium pyrrolidone carboxylate 0.100%
Alpha-tocopherol 0.050%
Glycyrrhetic acid 0.050%
Allantoin 0.050%
Lactic acid q.s. to pH 5.i
Squalane 7.000%
Salcare SC 91 2.500%
Preservative q.s.
Purified water q.s. to 100%

Claims

1. Topical compositions comprising Ν,Ο-carboxymethylchitosan and sucrose octasulphate sodium or potassium salt as active ingredients.
2. Compositions according to claim 1 wherein Ν,Ο-carboxymethylchitosan is present in weight percentages ranging from 0.005% to 8%, and sucrose octasulphate sodium or potassium salt is present in weight percentages ranging from 0.010% to 5.0%.
3. Compositions according to claim 2 wherein Ν,Ο-carboxymethylchitosan is present in weight percentages ranging from 0.009%) to 5% w/w, and sucrose octasulphate sodium or potassium salt is present in weight percentages ranging from 0.050%) to 3.0%>.
4. Compositions according to claim 2 wherein Ν,Ο-carboxymethylchitosan is present in weight percentages ranging from 0.010%> to 3%, and sucrose octasulphate sodium or potassium salt is present in weight percentages ranging from 0.100% to 1.0%>.
5. Compositions according to the above claims in the form of lotions, gels, oil- in- water (o/w) or water-in-oil (w/o) emulsions, creams, ointments, sprays or foams.
6. Compositions according to one or more of the above claims containing water as carrier.
7. Compositions according to one or more of the above claims containing further active ingredients for use in dermatology and cosmetology.
8. Compositions according to one or more of the above claims for use for restoring the water homeostasis of the skin.
9. Compositions according to claim 8 for use in the treatment of redness, burns, bedsores, vascular conditions and all irritative conditions of the skin and mucous membranes when induced by impaired transepidermal water loss.
PCT/EP2018/060310 2017-05-03 2018-04-23 Topical compositions designed to maintain and restore the water homeostasis of the skin WO2018202456A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102017000047632A IT201700047632A1 (en) 2017-05-03 2017-05-03 TOPIC COMPOSITIONS TO MAINTAIN AND RESTORE THE HYDRO-MOISTIC SKIN HOMEOSTASIS
IT102017000047632 2017-05-03

Publications (1)

Publication Number Publication Date
WO2018202456A1 true WO2018202456A1 (en) 2018-11-08

Family

ID=59811930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/060310 WO2018202456A1 (en) 2017-05-03 2018-04-23 Topical compositions designed to maintain and restore the water homeostasis of the skin

Country Status (4)

Country Link
AR (1) AR111666A1 (en)
IT (1) IT201700047632A1 (en)
TW (1) TW201842917A (en)
WO (1) WO2018202456A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619995A (en) 1984-12-24 1986-10-28 Nova Chem Limited N,O-carboxymethyl chitosan and preparative method therefor
EP0640346A1 (en) * 1987-12-21 1995-03-01 BM Research A/S Uses of sulphated sugars against inflammation
WO1998022114A1 (en) * 1996-11-15 1998-05-28 Dumex-Alpharma A/S A method for promoting tissue repair
WO2014085421A1 (en) * 2012-11-28 2014-06-05 Zarzatech, Inc. Treatment of skin or mucosal pathology

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619995A (en) 1984-12-24 1986-10-28 Nova Chem Limited N,O-carboxymethyl chitosan and preparative method therefor
EP0640346A1 (en) * 1987-12-21 1995-03-01 BM Research A/S Uses of sulphated sugars against inflammation
WO1998022114A1 (en) * 1996-11-15 1998-05-28 Dumex-Alpharma A/S A method for promoting tissue repair
WO2014085421A1 (en) * 2012-11-28 2014-06-05 Zarzatech, Inc. Treatment of skin or mucosal pathology

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Excipients", PHARMACEUTICAL PRESS
"Remington, The Science and Practice of Pharmacy"
WERNER MÜLLER ET AL: "A new printable and durable N,O-carboxymethyl chitosan-Ca2+-polyphosphate complex with morphogenetic activity", J. MATER. CHEM. B, 11 February 2015 (2015-02-11), pages 1722 - 173, XP055434020, Retrieved from the Internet <URL:http://impactfactor.org/PDF/IJPCR/8/IJPCR,Vol8,Issue11,Article7.pdf> DOI: 10.1039/c4tb01586j *

Also Published As

Publication number Publication date
AR111666A1 (en) 2019-08-07
IT201700047632A1 (en) 2018-11-03
TW201842917A (en) 2018-12-16

Similar Documents

Publication Publication Date Title
US10966927B2 (en) Petrolatum-based delivery systems and for active ingredients
JP2681527B2 (en) Topical for promoting cell activity
US11969405B2 (en) Method of treatment of topical dermatologic acne using a cream composition and method of manufacture
EP3175888B1 (en) Compositions containing polymeric sulfur and uses thereof
US8846646B2 (en) Topical treatment of skin infection
DE102008036725B4 (en) Pharmaceutical composition for nasal application
WO2012138441A1 (en) Composition and method for topical treatment of skin lesions
JP3253982B2 (en) Acne cosmetics
Hopkins et al. Fungistatic agents for treatment of dermatophytosis
WO2018202456A1 (en) Topical compositions designed to maintain and restore the water homeostasis of the skin
EP2737902A1 (en) Compositions comprising cimetidine and n,o-carboxymethyl chitosan for the prevention and therapy of pathologies of the skin and the mucous membranes and in the odontostomatological field
Mishra et al. Topical antibiotics and semisolid dosage forms
WO2016086280A1 (en) Dermatological composition and use thereof
US20220062157A1 (en) Oral articles and methods of use
GR1009906B (en) Paste for the prevention and therapy of bedsores and decubitus ulcers - production method thereof
DK176050B1 (en) Use of cyanoacrylates in the manufacture of a medicament for the treatment of diseases manifesting themselves in and/or damaging cutaneous tissue e.g. viral infections
KR20240005828A (en) wound care composition
JP6016085B2 (en) Antifungal composition for external use and method for applying antifungal composition for external use
JP2002338476A (en) Prophylactic and therapeutic agent for itching accompanied by kidney dialysis
KR20070070281A (en) A composition for suppressing atopic dermatitis, acne, and dermatophytosis using green intellectual nano drug delivery system
CA2746717A1 (en) Anti-fungal diaper rash creme
JP2004224745A (en) Anti-pruritus agent
MX2011008254A (en) Composition for the cellular regeneration of topic application for treating different skin disorders.
JPS6334849B2 (en)
ITRM20130429A1 (en) PHARMACEUTICAL COMPOSITION FOR TOPICAL USE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18723429

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18723429

Country of ref document: EP

Kind code of ref document: A1